Guide
Hitting a Plateau on a GLP-1: What the Evidence Says
Weight loss on these drugs is not linear, and the trial curves flatten well before 72 weeks. A plateau is often the expected shape of the response rather than a failure —
Weight loss on these drugs is not linear, and the trial curves flatten well before 72 weeks. A plateau is often the expected shape of the response rather than a failure — but it is a reason to talk to your prescriber about dose, adherence and what your target actually is.
The trial curves are the useful context
SURMOUNT-1 ran 72 weeks and reported mean reductions of about 15.0%, 19.5% and 20.9% at 5, 10 and 15 mg. Those are endpoints, not steady rates. The curves rise steeply early and flatten substantially in the second half.
So a slowdown after several months is consistent with what the trials show. It is not evidence that the medication has stopped working, and it is not by itself a reason to escalate.
What a plateau might actually be
The expected shape of the response. Most likely, and requires nothing.
An incomplete titration. If you are still below a recommended maintenance dosage, the label allows increases no sooner than every four weeks based on tolerability and response.
Reaching your body's new set point. Trial means contain wide individual variation, and some people plateau well below the average.
Something unrelated. Other medications, thyroid function, sleep, alcohol, or a change in circumstances. This is why a plateau is a conversation with a clinician rather than a dose decision made alone.
What the withdrawal evidence adds
SURMOUNT-4 found that participants withdrawn from tirzepatide regained 14% of body weight over the following year, while those continuing lost a further 5.5%. So a plateau is not the same as having finished — the continuing group in that trial was still losing slowly.
That also reframes the plateau financially. If maintaining the result requires maintaining the medication, the question at a plateau is what an indefinite monthly cost looks like, not whether the last three months were worth it.
What to bring to your prescriber
- Your current dose, and how long you have held it.
- Roughly how your weight has moved over the last eight to twelve weeks.
- Whether side effects are limiting you.
- What your target is, and whether it is still the right one.
- Whether anything else changed — medication, sleep, circumstances.
What not to do
Do not increase your own dose. Do not stack a compounded product on top of a branded one — the label states coadministration with another GLP-1 receptor agonist is not recommended. And do not switch providers purely to access a higher dose without a clinician agreeing it is appropriate.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- SURMOUNT-3 Tirzepatide Trial ExplainedResearch
- SURMOUNT-1 Tirzepatide Trial ExplainedResearch
- SUMMIT Trial: Tirzepatide and HFpEFResearch
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- Retatrutide Phase 3 Results and How It ComparesResearch
- Oral Tirzepatide and Sublingual Products: What Evidence Exists?Pillar / Money
- Microdose Tirzepatide: The Evidence GapJournal
GLP-1 Tirzepatide Review. “Hitting a Plateau on a GLP-1: What the Evidence Says.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/glp1-plateau/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.